Research Article
Interleukin 28B Gene Polymorphism and Association with Chronic Hepatitis C Therapy Results in Latvia
Table 1
Baseline characteristics of the patient’s profile.
| | CC | NON-CC | TOTAL |
| Average age, years | 35 | 37 | 37 (18–68) | No. of patients, >40years | 15 (33%) | 40 (42%) | 54 (39%) | Male sex | 27 (59%) | 57 (59%) | 84 (59%) | BMI, kg/m2 | 25.2 | 26.2 | 25.9 | BMI, >30 kg/m2 | 5 (11%) | 12 (13%) | 17 (12%) | Genotype 1 | 21 (46%) | 66 (69%) | 87 (61%) | Genotype 2, 3 | 25 (54%) | 30 (31%) | 55 (39%) | HCV-RNA, ×106 IU/mL (Genotype1) | 2.78 | 2.19 | 2.33 | HCV-RNA, >600,000 IU/mL (Genotype 1) | 18 (39%) | 47 (49%) | 65 (46%) | ALT, U/L | 112 (17–325) | 104 (22–447) | 106 (17–447) | ALT, >ULN | 43 (93%) | 85 (88%) | 128 (90%) | GGT, U/L | 46.8 (9–228) | 88 (6–526) | 75 (6–526) | GGT, >ULN | 11 (24%) | 40 (42%) | 51 (36%) | Cholesterol, mM/L | 4.14 (2.09–7.35) | 4.6 (2.46–8.17) | 4.48 (2.09–8.17) | Triglycerides, mM/L | 1.17 (0.28–4.06) | 1.17 (0.3–5.44) | 1.11 (0.28–5.44) | Liver fibrosis* (Knodell) F0 F1 F3 F4 | 0.975 (0–3) 9 (21.9%) 28 (68.3%) 4 (9.7%) 0 | 1.2 (0–4) 21 (24.7%) 47 (55.3%) 12 (14%) 5 (5.9%) | 1.13 (0–4) 30 (23.8%) 75 (59.5%) 16 (12.7%) 5 (3.9%) | HAI index* (Knodell) | 6.44 (1–12) | 6.54 (2–13) | 6.5 (1–13) | Steatosis* > grade 0 | 34 (83%) | 65 (76.5%) | 99 (78.6%) | SVR | 34 (74%) | 50 (52%) | 84 (59%) |
|
|
*Missing data: histology (non-CC), (CC).
|